Skip to main content
Clinical Trials/NCT00006205
NCT00006205
Unknown
Phase 2

Combining Medications Treatment for Alcoholism

Bankole Johnson1 site in 1 country320 target enrollmentMarch 2005

Overview

Phase
Phase 2
Intervention
ondansetron + cognitive behavioral therapy
Conditions
Alcoholism
Sponsor
Bankole Johnson
Enrollment
320
Locations
1
Primary Endpoint
Self-report measures of alcohol-related problems and consumption, Objective measures of alcohol consumption
Last Updated
13 years ago

Overview

Brief Summary

The purpose of this study is to learn whether ondansetron and topiramate either alone or in combination is safe and effective in the treatment of alcohol dependence. This 13 week out-patient clinical trial is randomized, double-blind, and placebo-controlled. There are post-study follow up visits 1, 2 and 3 months after the end of the study. Participants will receive ondansetron and topiramate either alone or in combination or a placebo coupled with psychotherapy.

Detailed Description

This study is a 13 week clinical trial. During the 13 weeks participants receive placebo, ondansetron and topiramate alone or in combination. During the 13 weeks participants come to an outpatient clinic to receive the study medication, physical checks, and cognitive behavioral therapy. The duration of the weekly visit is 3 hours. There is a 1, 2, and 3 month post-study follow up visit. Screening for this study is initially done over the telephone and takes 15-20 minutes. If there is nothing found to make someone ineligible to participate, they come to the out-patient clinic for a more thorough in-clinic screening.

Registry
clinicaltrials.gov
Start Date
March 2005
End Date
December 2013
Last Updated
13 years ago
Study Type
Interventional
Study Design
Factorial
Sex
All

Investigators

Responsible Party
Sponsor Investigator
Principal Investigator

Bankole Johnson

Chair of Psychiatry and Neurobehavioral Sciences

University of Virginia

Eligibility Criteria

Inclusion Criteria

  • Current diagnosis of alcohol dependence and drinking greater than or equal to 14 alcohol drinks/week for women and greater than or equal to 21 alcohol drinks/week for men in the last 30 days.
  • Provide a written, informed consent.
  • Good physical health and must weigh within at least 40 kg and no more than 140 kg.
  • Literate in English and able to read, understand, follow instructions, and complete questionnaires accurately.
  • Willingness to participate in behavioral treatments for alcoholism.
  • Provide evidence of stable residence in the last month prior to enrollment in the study and have no plans to move during the next three months.

Exclusion Criteria

  • Please contact site for additional information

Arms & Interventions

Ondansetron

Ondansetron + cognitive behavioral therapy

Intervention: ondansetron + cognitive behavioral therapy

Topiramate

Topiramate + cognitive behavioral therapy

Intervention: topiramate + cognitive behavioral therapy

Placebo

Placebo + cognitive behavioral therapy

Intervention: Placebo + cognitive behavioral therapy

Ondansetron + Topiramate

Ondansetron + Topiramate + cognitive behavioral therapy

Intervention: ondansetron + topiramate + cognitive behavioral therapy

Outcomes

Primary Outcomes

Self-report measures of alcohol-related problems and consumption, Objective measures of alcohol consumption

Time Frame: Throughout the study

Drinks per drinking day, Drinks per day, Percent Days Abstinent, BAC, CDT, GGT

Secondary Outcomes

  • Medication compliance, alcohol craving, social functioning, quality of life, alcohol withdrawal, attendance at psychosocial services, pre-morbid risk factors(Throughout the study)

Study Sites (1)

Loading locations...

Similar Trials